Antibody persistence after primary and booster doses of a quadrivalent meningococcal conjugate vaccine in adolescents
- PMID: 24911896
- DOI: 10.1097/INF.0000000000000438
Antibody persistence after primary and booster doses of a quadrivalent meningococcal conjugate vaccine in adolescents
Abstract
Background: The aim of this study was to evaluate antibody persistence 5 years after primary vaccination with the quadrivalent meningococcal conjugate vaccines MenACWY-CRM or MenACWY-D and 2 years after a booster dose of MenACWY-CRM, in the context of a phase 3 study.
Methods: Subjects (aged 19.2 ± 2.3 years) were assigned to 5 groups according to whether they had previously received primary vaccination (at 14.2 ± 2.2 years) with MenACWY-CRM (N = 131) or MenACWY-D (N = 76), a booster dose of MenACWY-CRM 3 years after primary vaccination with MenACWY-CRM (N = 44) or MenACWY-D (N = 31) or no vaccination (N = 107). The immunogenicity measures were percentages of subjects with serum bactericidal activity (hSBA) ≥ 1:8 for serogroups A, C, W and Y and hSBA geometric mean titers. Comparisons with age-matched, vaccine-naive subjects were performed.
Results: A majority of subjects vaccinated 5 years previously maintained hSBA ≥ 1:8 against serogroups C, W and Y in the MenACWY-CRM (59%-82%) and MenACWY-D groups (54%-73%); this was lower for serogroup A in both groups. There was a decline in antibody titers after primary vaccination, especially in the first 2 years postprimary vaccination, with steady concentrations during the next 3 years. Two years after MenACWY-CRM booster vaccination the percentages of subjects with hSBA ≥ 1:8 ranged from 77% to 100% across serogroups and geometric mean titers were 2.5- to 8-fold higher than prebooster values across serogroups.
Conclusions: Booster vaccination with MenACWY-CRM elicited a robust immune response during the 2-year follow-up period, irrespective of previous vaccination.
Similar articles
-
Antibody persistence and booster response of a quadrivalent meningococcal conjugate vaccine in adolescents.J Pediatr. 2014 Jun;164(6):1409-15.e4. doi: 10.1016/j.jpeds.2014.02.025. Epub 2014 Mar 20. J Pediatr. 2014. PMID: 24657122 Clinical Trial.
-
Antibody persistence and response to a booster dose of a quadrivalent conjugate vaccine for meningococcal disease in adolescents.Pediatr Infect Dis J. 2013 Apr;32(4):e170-7. doi: 10.1097/INF.0b013e318279ac38. Pediatr Infect Dis J. 2013. PMID: 23114372
-
Antibody persistence 5 years after vaccination at 2 to 10 years of age with Quadrivalent MenACWY-CRM conjugate vaccine, and responses to a booster vaccination.Vaccine. 2015 Apr 27;33(18):2175-82. doi: 10.1016/j.vaccine.2015.02.049. Epub 2015 Mar 2. Vaccine. 2015. PMID: 25744224 Clinical Trial.
-
Persistence of the immune response after MenACWY-CRM vaccination and response to a booster dose, in adolescents, children and infants.Hum Vaccin Immunother. 2016 May 3;12(5):1300-10. doi: 10.1080/21645515.2015.1136040. Epub 2016 Feb 1. Hum Vaccin Immunother. 2016. PMID: 26829877 Free PMC article. Review.
-
An update of clinical experience with the quadrivalent meningococcal ACWY-CRM conjugate vaccine.Expert Rev Vaccines. 2018 Oct;17(10):865-880. doi: 10.1080/14760584.2018.1521280. Epub 2018 Sep 27. Expert Rev Vaccines. 2018. PMID: 30198805 Review.
Cited by
-
Evaluation of Meningococcal Serogroup C Bactericidal Antibodies after Primary Vaccination: A Multicentre Study, Italy.Vaccines (Basel). 2022 May 14;10(5):778. doi: 10.3390/vaccines10050778. Vaccines (Basel). 2022. PMID: 35632534 Free PMC article.
-
Modeling the public health impact of different meningococcal vaccination strategies with 4CMenB and MenACWY versus the current toddler MenACWY National Immunization Program in Chile.Hum Vaccin Immunother. 2021 Dec 2;17(12):5603-5613. doi: 10.1080/21645515.2021.1996808. Epub 2021 Dec 10. Hum Vaccin Immunother. 2021. PMID: 34890520 Free PMC article.
-
[Health Technology Assessment (HTA) of the introduction of additional cohorts for anti-meningococcal vaccination with quadrivalent conjugate vaccines in Italy].J Prev Med Hyg. 2021 May 13;62(1 Suppl 1):E1-E128. doi: 10.15167/2421-4248/jpmh2021.62.1s1. eCollection 2021 Mar. J Prev Med Hyg. 2021. PMID: 34622076 Free PMC article. Italian. No abstract available.
-
Meningococcal disease and vaccination in college students.Hum Vaccin Immunother. 2021 Nov 2;17(11):4675-4688. doi: 10.1080/21645515.2021.1973881. Epub 2021 Oct 6. Hum Vaccin Immunother. 2021. PMID: 34613863 Free PMC article. Review.
-
A Decade of Fighting Invasive Meningococcal Disease: A Narrative Review of Clinical and Real-World Experience with the MenACWY-CRM Conjugate Vaccine.Infect Dis Ther. 2022 Apr;11(2):639-655. doi: 10.1007/s40121-021-00519-2. Infect Dis Ther. 2022. PMID: 34591258 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources